CONCEIVE (outCOme of pregNanCies in patiEnts with Ibd under VEdolizumab

• Research type

  Research Study

• Full title

  Outcome of pregnancies in female IBD patients treated with vedolizumab (CONCEIVE)

• IRAS ID

  251254

• Contact name

  Naila Arebi

• Contact email

  naila.arebi@imperial.ac.uk

• Sponsor organisation

  London Northwest Healthcare NHS Trust

• Clinicaltrials.gov Identifier

  Project policy, S60985

• Duration of Study in the UK

  0 years, 5 months, 5 days

• Research summary

  Very few data are available regarding pregnancy outcomes in female patients with inflammatory bowel disease treated with vedolizumab. Given that patients typically present at an age which falls within child-bearing potential, it is important to provide information and advice patients and their partners about conception and the potential risks for both the mother and the (unborn) child.
  This is a retrospective data collection study. We will collect data on the outcome of pregnancies in patients treated with Vedolizumab and their new-born child.

• REC name

  North West - Haydock Research Ethics Committee

• REC reference

  18/NW/0702

• Date of REC Opinion

  20 Sep 2018

• REC opinion

  Favourable Opinion